1-7 of 7
Peter J. M. Valk
Close
Sort by
Journal Articles

DNA vs cDNA FLT3 -ITD allelic ratio and length measurements in adult acute myeloid leukemia

Clinical Trials & Observations
David G. J. Cucchi, Christian M. Vonk, Melissa Rijken, François G. Kavelaars, Pauline A. Merle, Elvira Verhoef, Bianca Venniker-Punt, Zinia J. Kwidama, Patrycja Gradowska, Bob Löwenberg, Jeroen J. W. M. Janssen, Jacqueline Cloos, Peter J. M. Valk
Journal: Blood Advances
Blood Adv (2021) 5 (21): 4476–4479.
https://doi.org/10.1182/bloodadvances.2021004980
Published: 2021
Includes: Supplemental data
Journal Articles

Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification

Clinical Trials & Observations
Inge van der Werf, Anna Wojtuszkiewicz, Manja Meggendorfer, Stephan Hutter, Constance Baer, Martijn Heymans, Peter J. M. Valk, Wolfgang Kern, Claudia Haferlach, Jeroen J. W. M. Janssen, Gert J. Ossenkoppele, Jacqueline Cloos, Torsten Haferlach
Journal: Blood Advances
Blood Adv (2021) 5 (17): 3254–3265.
https://doi.org/10.1182/bloodadvances.2021004556
Published: 2021
Includes: Supplemental data
Journal Articles

Disruption of CSF-1R signaling inhibits growth of AML with inv(16)

Alexander Simonis, Norman F. Russkamp, Jan Mueller, C. Matthias Wilk, Mattheus H. E. Wildschut, Renier Myburgh, Nicole Wildner-Verhey van Wijk, Rouven Mueller, Stefan Balabanov, Peter J. M. Valk, Alexandre P. A. Theocharides, Markus G. Manz
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1273–1277.
https://doi.org/10.1182/bloodadvances.2020003125
Published: 2021
Includes: Supplemental data
Journal Articles

Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Clinical Trials & Observations
Bob Löwenberg, Thomas Pabst, Johan Maertens, Patrycja Gradowska, Bart J. Biemond, Olivier Spertini, Edo Vellenga, Laimonas Griskevicius, Lidwine W. Tick, Mojca Jongen-Lavrencic, Marinus van Marwijk Kooy, Marie-Christiane Vekemans, Walter J. F. M. van der Velden, Berna Beverloo, Lucienne Michaux, Carlos Graux, Dries Deeren, Okke de Weerdt, Joost W. J. van Esser, Mario Bargetzi, Saskia K. Klein, Alain Gadisseur, Peter E. Westerweel, Hendrik Veelken, Michael Gregor, Tobias Silzle, Daniëlle van Lammeren-Venema, Ine Moors, Dimitri A. Breems, Mels Hoogendoorn, Marie-Cecile J. C. Legdeur, Thomas Fischer, Juergen Kuball, Jan Cornelissen, Kimmo Porkka, Gunnar Juliusson, Peter Meyer, Martin Höglund, Bjorn T. Gjertsen, Jeroen J. W. M. Janssen, Gerwin Huls, Jakob Passweg, Jacqueline Cloos, Peter J. M. Valk, Catharina H. M. J. van Elssen, Markus G. Manz, Yngvar Floisand, Gert J. Ossenkoppele
Journal: Blood Advances
Blood Adv (2021) 5 (4): 1110–1121.
https://doi.org/10.1182/bloodadvances.2020003855
Published: 2021
Includes: Supplemental data
Journal Articles

Secondary CNL after SAA reveals insights in leukemic transformation of bone marrow failure syndromes

Clinical Trials & Observations
Laurent Schmied, Patricia A. Olofsen, Pontus Lundberg, Alexandar Tzankov, Martina Kleber, Jörg Halter, Mario Uhr, Peter J. M. Valk, Ivo P. Touw, Jakob Passweg, Beatrice Drexler
Journal: Blood Advances
Blood Adv (2020) 4 (21): 5540–5546.
https://doi.org/10.1182/bloodadvances.2020001541
Published: 2020
Includes: Supplemental data
Journal Articles

TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML

Clinical Trials & Observations
Jayakumar Vadakekolathu, Catherine Lai, Stephen Reeder, Sarah E. Church, Tressa Hood, Anbarasu Lourdusamy, Michael P. Rettig, Ibrahim Aldoss, Anjali S. Advani, John Godwin, Matthew J. Wieduwilt, Martha Arellano, John Muth, Tung On Yau, Farhad Ravandi, Kendra Sweet, Heidi Altmann, Gemma A. Foulds, Friedrich Stölzel, Jan Moritz Middeke, Marilena Ciciarello, Antonio Curti, Peter J. M. Valk, Bob Löwenberg, Ivana Gojo, Martin Bornhäuser, John F. DiPersio, Jan K. Davidson-Moncada, Sergio Rutella
Journal: Blood Advances
Blood Adv (2020) 4 (20): 5011–5024.
https://doi.org/10.1182/bloodadvances.2020002512
Published: 2020
Includes: Supplemental data
Journal Articles

Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS

Clinical Trials & Observations
Gerwin Huls, Dana A. Chitu, Thomas Pabst, Saskia K. Klein, Georg Stussi, Laimonas Griskevicius, Peter J. M. Valk, Jacqueline Cloos, Arjan A. van de Loosdrecht, Dimitri Breems, Danielle van Lammeren-Venema, Isabelle van Zeventer, Rinske Boersma, Mojca Jongen-Lavrencic, Martin Fehr, Mels Hoogendoorn, Markus G. Manz, Maaike Söhne, Rien van Marwijk Kooy, Dries Deeren, Marjolein W. M. van der Poel, Marie Cecile Legdeur, Lidwine Tick, Yves Chalandon, Emanuele Ammatuna, Sabine Blum, Bob Löwenberg, Gert J. Ossenkoppele
Journal: Blood Advances
Blood Adv (2020) 4 (18): 4267–4277.
https://doi.org/10.1182/bloodadvances.2020002846
Published: 2020
Includes: Supplemental data